{"id":"4ee995a145ad","type":"article","url":"https://hartvaat.nl/2026/04/20/stopstorm-stereotactische-bestraling-reduceert-refractaire-vt-met-80/","title":"STOPSTORM: stereotactische bestraling reduceert refractaire VT met 80%","title_en":"","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":["ventrikelfibrilleren"],"journal":"European heart journal","doi":"10.1093/eurheartj/ehag338","source_url":"https://doi.org/10.1093/eurheartj/ehag338","authors":["L H G van der Pol","Bartłomiej Tomasik","Wiert F Hoeksema","Stefano Mandija","Marcin Miszczyk","Melanie Grehn","Jasna But Hadzic","David Calvo","Chiara Crico","Jakub Cvek","David Duncker","Felix Hohendanner","Tomasz Jadczyk","Stefan Jaschik","David Krug","Mario Levis","Gaetano Maria De Ferrari","Pieter P G Postema","Luis Schiappacasse","Jingyang Xie","Maiwand Ahmadsei","Manuel Algara","Piedad Almendros Blanco","Matteo Anselmino","Bor Antolic","Brian V Balgobind","Jacek Bednarek","Judit Boda-Heggemann","Thomas B Brunner","Corrado Carbucicchio","Francesco Cellini","Marzia Cerrato","Marian Christoph","Stefanie Corradini","Maria Del Pino Alcantara","Lukasz Dolla","Veronica Dusi","Micaela Ebert","Olgun Elicin","Niccolò Giaj-Levra","Franziska Hausmann","Colien Hazelaar","Claudia Herrera Siklody","Gerhard Hindricks","Mauro Iori","Barbara A Jereczek-Fossa","Otakar Jiravsky","Joanna Kaminska","Gunther Klautke","Lukas Knybel","Boldizsar Kovacs","Mathieu Kruska","Annika Lattermann","Tomasz Latusek","Marc D Lemoine","Evgeny Lian","Michele Magnocavallo","Felix Mehrhof","Roland Merten","Giulio Molon","Jiri Plasek","Gustavo Pozo Rodigriuez","Javier Quesada-Ocete","Robert Rademaker","Dirk Rades","Coen R N Rasch","Ardan Saguner","Mateusz Sajdok","Daniel Scherr","Ajra Secerov Ermenc","Lukas Seiss","Moritz Sinner","Jorge Solana Munoz","Rachel M A Ter Bekke","Roland Tilz","Christian Veltmann","Adrian Zaman","Nicolaus Andratschke","Katja Zeppenfeld","Slawomir Blamek","Joost J C Verhoeff","Etienne Pruvot","Oliver Blanck","M F Fast"],"significance":9,"published":"2026-05-01","source_date":"2026-04-20","image":"","kennis":["https://hartvaat.nl/kennis/ritmestoornissen/katheterablatie-vt/","https://hartvaat.nl/kennis/diagnostiek/cardiale-mri/"],"congress":"","summary_en":"The European STOPSTORM registry followed 193 patients (88% male, 53% non-ischaemic cardiomyopathy) treated with stereotactic arrhythmia radioablation (STAR) for refractory ventricular tachycardia. Among 107 patients with ≥6-month follow-up, median VT burden fell 80% over the six months after STAR and 72% remained free of ICD shocks. Twelve serious adverse events were adjudicated as possibly or probably treatment-related (including pericardial effusion and coronary events); 12-month overall survival was 77%.","created":"2026-07-03T10:32:49Z","updated":"2026-07-03T13:31:45Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"Het Europese STOPSTORM-register volgde 193 patiënten (88% man, 53% niet-ischemische cardiomyopathie) na stereotactische arrhythmieradioablatie (STAR) voor refractaire ventriculaire tachycardie. Bij 107 patiënten met ≥6 maanden follow-up daalde de mediane VT-burden 80% in de zes maanden na STAR; 72% van hen bleef vrij van ICD-shocks. Twaalf ernstige bijwerkingen werden geadjudiceerd als mogelijk of waarschijnlijk behandelingsgerelateerd, waaronder pericardeffusie en coronaire events. De algemene 12-maandsoverleving was 77%.","abstract_original":"BACKGROUND AND AIMS: Stereotactic arrhythmia radioablation (STAR) is increasingly used for refractory ventricular tachycardia (VT), yet prospective multicentre outcome data remain limited. Here, the planned interim analysis of the prospective Standardized Treatment and Outcome Platform for Stereotactic Therapy Of Re-entrant tachycardia by a Multidisciplinary (STOPSTORM) registry is reported. METHODS: STOPSTORM is a European prospective, international, multicentre registry of patients treated with STAR. The primary efficacy endpoint was the change in sustained VT episode burden comparing the 6 months before versus the 6 months after STAR. The primary safety endpoint was the occurrence of serious adverse events (SAEs) adjudicated as possibly or probably treatment-related. Overall survival was assessed using time-to-event methods. RESULTS: Across 28 centres, 193 patients were included (mean age 68±9 years; 88% male; 53% non-ischaemic cardiomyopathy). Median follow-up was 19 months. Among 107 evaluable patients with ≥6-month follow-up, the median VT episode burden was reduced by 80% after STAR. Among patients surviving ≥6 months, 72% were free from implantable cardioverter-defibrillator (ICD) shock. In the full cohort, 12 SAEs were adjudicated as possibly or probably treatment-related, including pericardial effusion, coronary events, and early post-treatment ventricular arrhythmia. Overall survival probability was 77% at 12 months. CONCLUSIONS: In the largest prospective multicentre cohort reported to date, STAR was associated with a substantial reduction in VT burden and ICD shocks, with a low frequency of possibly or probably treatment-related SAEs."}